When biliary tract cancer carries high levels of HER2 protein, new targeted treatments are changing what doctors can offer patients. These innovative therapies focus specifically on cancer cells with this molecular feature, opening pathways that were not available just a few years ago.

When Cancer Meets Precision: Treatment That Targets What Makes Your Tumor Unique

Treating biliary tract cancer—a group of cancers affecting the bile ducts and gallbladder—has long been a significant challenge in oncology. When a tumor tests positive for HER2 (human epidermal growth factor receptor-2), a protein that can drive cancer growth, it presents both a concern and an opportunity. HER2-positive status means the cancer may behave more aggressively, but it also means the tumor has a specific target that newer medications can attack directly.^[1]

The main goals of treatment in HER2-positive biliary tract cancer include slowing down how fast the disease progresses, reducing symptoms that affect daily life, and extending survival while maintaining quality of life. Treatment approaches depend heavily on several factors: how advanced the cancer is when discovered, whether it can be surgically removed, the patient’s overall health, and importantly, the molecular characteristics of the tumor itself. This is where precision medicine comes into play—selecting therapies based on the specific genetic and molecular features of an individual’s cancer rather than using a one-size-fits-all approach.^[1]

In recent years, the medical community has recognized the importance of testing every biliary tract cancer for HER2 status. This testing, usually performed through methods called immunohistochemistry (which detects HER2 protein levels) or next-generation sequencing (which looks at genetic changes), helps doctors determine whether HER2-targeted treatments should be part of the care plan. Not all biliary tract cancers are HER2-positive, but when they are, specific treatments designed to block this protein’s activity can make a meaningful difference.^[4]

Today’s treatment landscape includes standard chemotherapy approaches approved by medical societies worldwide, as well as cutting-edge therapies being tested in clinical trials. These clinical trials are research studies designed to evaluate whether new treatments are safe and effective before they become widely available. For patients with HER2-positive disease, participating in such trials may provide access to promising new options.^[1]

Standard Treatment: The Foundation of Care

For many years, chemotherapy has been the cornerstone of treatment for advanced biliary tract cancer. The most widely used first-line regimen combines two chemotherapy drugs: gemcitabine and cisplatin. This combination, often referred to as GEMCIS, was established through a landmark study called the ABC-02 trial and remains a recommended standard worldwide. Gemcitabine works by interfering with cancer cells’ ability to copy their DNA and divide, while cisplatin damages the DNA inside cancer cells, preventing them from growing and multiplying.^[1][7]

Treatment with gemcitabine and cisplatin is typically given through an intravenous infusion in cycles, with each cycle repeated every few weeks. The duration of therapy varies depending on how well the cancer responds and how well the patient tolerates the treatment. Some patients continue for several months, while others may switch to different approaches if the cancer progresses or side effects become too burdensome.^[1]

In recent years, adding immunotherapy to this chemotherapy backbone has become a new standard for many patients. Immunotherapy drugs work by helping the patient’s own immune system recognize and attack cancer cells. Two specific medications in this category have shown benefit when combined with gemcitabine and cisplatin: durvalumab (an anti-PD-L1 antibody) and pembrolizumab (an anti-PD-1 antibody). The TOPAZ-1 trial demonstrated that adding durvalumab to chemotherapy improved survival outcomes, leading to regulatory approval of this combination. Results from this study showed that the three-year overall survival rate approximately doubled compared to chemotherapy alone, though long-term survival remains limited, with about one in five patients surviving beyond three years.^[1][7][11]

When cancer continues to grow despite first-line treatment, second-line options typically include different chemotherapy regimens. A commonly used approach is mFOLFOX, which combines several drugs including oxaliplatin and fluorouracil. This regimen was validated in the ABC-06 trial and is often given along with supportive care aimed at managing symptoms and maintaining quality of life.^[1][7]

However, for patients whose tumors test positive for specific molecular targets—including HER2—treatment may include targeted therapies rather than or in addition to traditional chemotherapy. These targeted approaches are designed to block specific proteins or pathways that cancer cells depend on for growth. Beyond HER2, other targets that can be addressed with approved therapies include FGFR2 fusions, IDH1 mutations, BRAF V600E mutations, NTRK fusions, and RET alterations. Each of these represents a different molecular weakness that can be exploited with the right medication.^[8][11]

Side effects from standard chemotherapy can be significant and affect patients’ daily lives. Common problems include lowered blood cell counts (which can increase infection risk and cause fatigue), nausea and vomiting, loss of appetite, hair loss, and nerve damage causing numbness or tingling in hands and feet. Cisplatin specifically can affect kidney function and hearing. Immunotherapy adds its own potential side effects, which occur when the activated immune system mistakenly attacks normal tissues. These can include skin rashes, diarrhea, inflammation of the lungs or liver, and hormone-related problems affecting the thyroid or other glands. Most side effects are manageable with supportive medications and dose adjustments, but they require close monitoring by the healthcare team.^[1]

HER2-Targeted Therapy: A Game-Changer for Eligible Patients

Research has revealed that HER2 positivity in biliary tract cancer is not just a marker—it’s a negative prognostic factor, meaning patients with HER2-positive tumors who receive only standard chemotherapy tend to have shorter survival times compared to those with HER2-negative disease. One study showed that HER2-positive patients treated with chemotherapy alone had a median overall survival of just 8.1 months, compared to 17.1 months for HER2-negative patients. Their progression-free survival on first-line chemotherapy was also significantly shorter, at 5.1 months versus 7.4 months.^[4][12]

This sobering reality underscores why HER2-targeted treatments matter so much. When patients with HER2-positive biliary tract cancer receive therapies specifically designed to block HER2, their outcomes improve dramatically. The same study found that HER2-positive patients who received HER2-targeted therapy achieved survival outcomes comparable to HER2-negative patients—with median overall survival reaching 18.2 months. This represents more than a doubling of survival time compared to those who did not receive HER2-targeted treatment.^[4][12]

Treatment in Clinical Trials: The Frontier of Innovation

Clinical trials testing new HER2-targeted therapies for biliary tract cancer have brought several innovative approaches into development, with some already receiving regulatory approval. These studies typically progress through distinct phases, each designed to answer specific questions about a new treatment.

Phase I trials focus primarily on safety. Researchers test different doses of a new drug in a small group of patients to find the highest dose that can be given without causing severe side effects. These studies also provide early information about how the drug behaves in the body—how it’s absorbed, distributed, and eliminated.^[12]

Phase II trials evaluate whether the drug actually works against cancer. These studies enroll more patients and measure outcomes like how many tumors shrink, how long patients live without their cancer progressing, and overall survival. Phase II trials often focus on patients with specific molecular characteristics, such as HER2 positivity, to determine if the treatment benefits that particular group.^[1]

Phase III trials compare the new treatment directly to current standard therapies in large groups of patients. These randomized studies provide the strongest evidence about whether a new approach is better than existing options. If successful, phase III results typically form the basis for regulatory approval.^[1]

Phase IV trials continue after a drug is approved, monitoring its long-term effectiveness and safety in real-world practice across diverse patient populations.^[1]

Zanidatamab: A Bispecific Antibody Targeting HER2

One of the most significant advances for HER2-positive biliary tract cancer is zanidatamab, which received FDA approval in November 2024. Zanidatamab represents a new class of cancer medicine called bispecific antibodies. Unlike traditional antibodies that bind to a single location on a target protein, zanidatamab can attach to two different regions of the HER2 protein simultaneously. This dual binding creates a stronger grip on HER2-positive cancer cells and triggers multiple mechanisms to stop their growth.^[2][6][14]

When zanidatamab binds to HER2, it blocks signals that tell cancer cells to divide and survive. It also helps recruit immune system cells to attack the tumor. Additionally, the drug causes HER2 proteins on the cell surface to be pulled inside and degraded, further reducing the cancer cell’s ability to receive growth signals. This triple action makes zanidatamab effective even in some cancers that have become resistant to older HER2-targeted drugs.^[14][15]

The approval was based on results from the HERIZON-BTC-01 study, a Phase II clinical trial that enrolled 87 patients with HER2-positive biliary tract cancer whose disease had progressed despite previous treatments. To be eligible, patients needed tumors with high HER2 expression, typically defined as a score of 3+ on immunohistochemistry testing or 2+ with positive amplification on a specialized genetic test called in situ hybridization. All participants had already received at least one prior line of treatment, often including chemotherapy.^[5][9][14]

The results were encouraging. Among patients treated with zanidatamab, a significant proportion experienced tumor shrinkage. The treatment demonstrated meaningful clinical benefit, with many patients living longer without their disease progressing compared to what would be expected with standard options at that stage. The drug also showed a manageable safety profile, with most side effects being tolerable and temporary.^[5][9][14]

Zanidatamab is administered as an intravenous infusion every two weeks. Dose optimization studies have established that 20 milligrams per kilogram of body weight every two weeks provides the best balance between effectiveness and tolerability. The treatment continues as long as it’s working and patients are tolerating it well.^[12][14]

While zanidatamab was initially approved for patients whose cancer had already progressed on other treatments, researchers are now testing whether starting this therapy earlier—perhaps in the first-line setting alongside chemotherapy—might produce even better results. Clinical trials are ongoing to explore these possibilities in the United States, Europe, and other regions worldwide.^[1][11]

Other HER2-Targeted Approaches Under Investigation

Beyond zanidatamab, several other HER2-directed therapies are being studied in biliary tract cancer clinical trials. The landscape of HER2-targeted treatment includes various drug types, each with distinct mechanisms of action.

Antibody-drug conjugates represent another innovative approach. These molecules combine a HER2-targeting antibody with a powerful chemotherapy drug. The antibody portion acts like a guided missile, delivering the toxic drug payload directly to HER2-positive cancer cells while sparing normal tissues. This targeted delivery can make the chemotherapy more effective while potentially reducing side effects compared to traditional chemotherapy that circulates throughout the body.^[1]

Other clinical trials are evaluating combinations of HER2-targeted drugs with immunotherapy or with other targeted agents. The rationale behind combination approaches is that attacking cancer through multiple mechanisms simultaneously may be more effective than using single agents. Some tumors might escape one treatment pathway but remain vulnerable to another, so combining therapies can prevent or delay resistance.^[1]

Researchers are also investigating whether HER2-targeted treatments can benefit patients whose tumors have lower levels of HER2 expression—not meeting the traditional threshold for HER2-positivity but still expressing some HER2 protein. These HER2-low tumors represent a newly recognized category that might respond to certain HER2-directed therapies, particularly newer antibody-drug conjugates designed to work at lower target expression levels.^[1]

Expanding HER2 Research Beyond Biliary Tract Cancer

The success of HER2-targeted treatments in biliary tract cancer has generated interest in testing these approaches in other cancer types where HER2 is present. Clinical trials are now enrolling patients with HER2-positive breast cancer, gastric and gastroesophageal cancers, lung cancers, colorectal cancers, ovarian cancers, and pancreatic cancers. These basket trials—studies that group patients by molecular marker rather than cancer location—reflect the precision medicine principle that targeting the molecular driver may be more important than the organ where cancer originated.^[14][15]

For biliary tract cancer specifically, ongoing trials are testing whether bringing HER2-targeted therapy into earlier lines of treatment will improve outcomes. Studies are examining combinations of zanidatamab or other HER2 inhibitors with standard chemotherapy and immunotherapy as initial treatment for newly diagnosed advanced disease. If these trials succeed, HER2-targeted therapy could become part of first-line standard care rather than being reserved for later treatment lines.^[11]

The Importance of Molecular Testing

None of these targeted treatment advances matter unless tumors are properly tested. Biomarker testing—analyzing tumor samples to identify specific genetic mutations, protein expression patterns, and other molecular features—has become essential in modern cancer care. For biliary tract cancer, comprehensive testing should ideally be performed at diagnosis, before starting any treatment.

Testing for HER2 can be done through several methods. Immunohistochemistry measures how much HER2 protein is present on the surface of cancer cells, scoring results from 0 (none) to 3+ (strong overexpression). Next-generation sequencing looks directly at the genetic code to identify amplification of the ERBB2 gene or mutations that might make the protein more active. In situ hybridization is another technique that can detect gene amplification. Often, multiple testing methods are used together to provide the most accurate assessment.^[4][12]

Comprehensive genomic profiling—using next-generation sequencing to analyze many genes simultaneously—is increasingly recommended because it can identify not only HER2 alterations but also other actionable targets like FGFR2 fusions, IDH1 mutations, BRAF mutations, NTRK fusions, and others. This broad testing approach ensures that no potential treatment opportunity is missed. Testing is typically covered by insurance when done to guide treatment decisions for an established cancer diagnosis.^[1][8]

Most Common Treatment Methods

• Chemotherapy
  • Gemcitabine combined with cisplatin (GEMCIS) as first-line standard treatment, established by the ABC-02 trial
  • mFOLFOX regimen (oxaliplatin, fluorouracil, and leucovorin) as second-line therapy following the ABC-06 trial results
  • These drugs work by damaging cancer cell DNA and interfering with cell division
• Chemoimmunotherapy
  • Durvalumab (anti-PD-L1 antibody) plus gemcitabine and cisplatin, approved based on the TOPAZ-1 trial
  • Pembrolizumab (anti-PD-1 antibody) combined with chemotherapy
  • These combinations activate the immune system to recognize and attack cancer cells while chemotherapy damages them directly
• HER2-Targeted Therapy
  • Zanidatamab, a bispecific antibody that binds two different sites on the HER2 protein simultaneously
  • Works by blocking HER2 signaling pathways, recruiting immune cells to attack tumor, and causing internalization and degradation of HER2 proteins
  • Given as intravenous infusion at 20 mg/kg every two weeks for patients with HER2-positive disease (IHC 3+ or 2+/ISH+)
  • Approved for advanced HER2-positive biliary tract cancer after prior treatment, based on HERIZON-BTC-01 trial results
• Other Targeted Therapies
  • FGFR2 inhibitors (pemigatinib, futibatinib) for tumors with FGFR2 fusions, producing response rates near 40%
  • IDH1 inhibitors for tumors with IDH1 mutations
  • BRAF inhibitors for tumors with BRAF V600E mutations
  • NTRK inhibitors for tumors with NTRK fusions
  • RET inhibitors for tumors with RET alterations